| Date |
Speakers(s) |
Program
Topic |
 |
| January
2010 |
Tom White, PhD
CSO & SVP
Celera Corporation |
Genomic and Proteomic Biomarkers that Predict Risk for Diseases and the Outcome of Drug Therapy |
| February
2010 |
Maria Walker
Senior Director, Venture Capital Practice
KPMG |
Everthing You Ever Wanted to Know About Venture Capital But Was Afraid to Ask |
| March
2010 |
Steve Rosenberg
Chief Scientific Officer
CardioDx |
Personalized Medicine: Yesterday, Today, and Tomorrow |
| April
2010 |
Jean Deleage, Ph.D.
Founding Partner & Managing Director
Alta Partners |
Biotechnology Investing from 1976 to the Present: Successes and Lessons Learned |
| May 2010 |
Philip D. Gregory, D. Phil.
Chief Scientific Officer and Vice President, Research
Sangamo BioSciences, Inc |
ZFP Therapeutics - Exploiting DNA as a Platform for Drug Development |
| June 2010 |
Hing Sham, Ph.D.
Senior Vice President, Chemical Sciences
Elan Pharmaceuticals |
Discovery of Two Generations of HIV Protease Inhibitors |
| July 2010 |
Andrew R. Allen, M.D., Ph.D.
Chief Medical Officer and Executive Vice President
Clovis Oncology, Inc. |
Personalized Cancer Medicine - Will the Exception Become the Norm, and When? |
| August 2010 |
Marc Tessier-Lavigne, Ph.D.
Executive Vice President, Research and Chief Scientific Officer
Genentech |
Axon Guidance Mechanisms in Brain Wiring, Neural Repair and Antiangiogenic Therapy |
| September 2010 |
Gideon Bollag, Ph.D.
Senior Vice President of Research
Plexxikon |
Kinase Drug Development |
| October 2010 |
Donald Francis, M.D., D.Sc.
Executive Director
Global Solutions for Infectious Diseases |
Vaccines for Less Developed Country Diseases: A New Era for Discovery and Development |
| November 2010 |
Jeffrey Glenn, M.D., Ph.D.
Associate Professor, Stanford University School of Medicine and Director of the Center for Global Hepatitis and Liver Tissue Engineering
Stanford University |
Translating Molecular Virology into Novel Therapies for Hepatitis |
| December 2010 |
Bryan Roberts, Ph.D.
Partner
Venrock |
Tomorrow for Biotech: Dawn, Dusk, or the Twilight Zone? |
